Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

TCR2 Therapeutics Inc. (TCRR)

20.32   0.97 (5.01%) 09-30 18:07
Open: 19.46 Pre. Close: 19.35
High: 20.42 Low: 19.46
Volume: 153,067 Market Cap: 678M
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 71 full-time employees. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The firm has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The firm has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.686 - 19.783 19.783 - 19.861
Low: 18.123 - 18.249 18.249 - 18.352
Close: 19.433 - 19.635 19.635 - 19.799

Technical analysis

as of: 2020-09-30 4:47:00 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 24.46     One year: 28.57
Support: Support1: 18.41    Support2: 16.85
Resistance: Resistance1: 20.94    Resistance2: 24.46
Pivot: 18.97
Moving Average: MA(5): 19.41     MA(20): 18.93
MA(100): 15.25     MA(250): 14.12
MACD: MACD(12,26): 0.47     Signal(9): 0.45
Stochastic oscillator: %K(14,3): 74.23     %D(3): 67.44
RSI: RSI(14): 55.29
52-week: High: 20.94  Low: 5.84  Change(%): 20.3
Average Vol(K): 3-Month: 36432  10-Days: 30838

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
TCRR has closed below upper band by 28.5%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 29 Sep 2020
How Much Of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Do Insiders Own? - Simply Wall St

Tue, 29 Sep 2020
TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit - GlobeNewswire

Mon, 21 Sep 2020
Are Investors Coy about TCR2 Therapeutics Inc. (NASDAQ:TCRR)? - Stocks Register

Tue, 08 Sep 2020
TCR2 Therapeutics to Participate in Two Upcoming Conferences in September - Stockhouse

Tue, 28 Jul 2020
TCR² Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire

Mon, 27 Jul 2020
TCR2 Therapeutics' TC-210 successful in mid-stage cancer study - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 33
Shares Float (M) 14
% Held by Insiders 5.58
% Held by Institutions 84.47
Shares Short (K) 1,470
Shares Short P. Month (K) 1,320

Stock Financials

EPS -2.420
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 5.530
Profit Margin
Operating Margin
Return on Assets (ttm) -23.2
Return on Equity (ttm) -37.0
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.805
Qtrly Earnings Growth
Operating Cash Flow (M) -53
Levered Free Cash Flow (M) -37

Stock Valuations

PE Ratio -8.11
PEG Ratio
Price to Book value 3.55
Price to Sales
Price to Cash Flow -12.39

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.